IXINITY® dosing & administration.

Reconstitution Kit: Convenience in preparation.

  • Pre-assembled syringe with plunger attached
  • Secure syringe-to-vial connection
  • Vacuum seal for ease of drawing diluent into vial
  • Large (20 mL) LUER-LOK™ Administration Syringe included

See the INSTRUCTIONS FOR USE section of the IXINITY package insert for reconstitution, pooling, and administration instructions.

LUER-LOK™ is a trademark of Becton, Dickinson and Company Corporation.

Watch Brian Rodgers reconstitute IXINITY.

Planet-Friendly Packaging takes the patient's world into account.
IXINITY comes in a fully collapsible, 100% recyclable carton.

Flexibility of IXINITY vial strengths.

IXINITY is available in 500, 1000, and 1500 IU single-use vials, which are color-coded by vial strength.1

To order IXINITY, call your IXperience Concierge™ at 1​-8​55​-I​XIN​ITY (1​-85​5-​49​4-​648​9).

IXINITY can be refrigerated or stored at room temperature.

  • Store at 2–25°C (36–77°F); do not freeze.1
  • Keep the vial in its carton and protect from light.1
  • The reconstituted solution should be infused immediately or within 3 hours of storage at room temperature after reconstitution.1
  • Do not refrigerate after reconstitution.1

Custom Ancillaries—patients choose at no additional cost.

Patients choose the ancillary supplies they want at no cost to you or them.

We worked with patients to figure out how to create flexibility that puts them in control of the ancillary supplies delivered with IXINITY. Butterfly needles, alcohol wipes, gauzes, bandages, tourniquets? Patients choose which–and how often–they get them delivered.

Whatever patients decide, there's no cost to you or them. In fact, we all gain as we work together to improve the hemophilia B patient IXperience and reduce waste.

Custom Ancillaries include choice of:

  • Winged infusion sets
  • Sterile prep pad
  • Gauze
  • Bandages
  • Extra syringes
  • Flex wrap
  • Tourniquet
  • Other supplies as requested

To request custom ancillaries for your patients, please fill out the Custom Ancillary Request Form and fax it to 1​-8​88​-7​47​-9​329 according to the instructions on the form.

Explore more about IXINITY

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Expand

INDICATIONS AND USAGE: IXINITY® [Coagulation Factor IX (Recombinant)] Lyophilized Powder for Solution for Intravenous Injection is a coagulation factor IX (recombinant) indicated in adults and children ≥12 years of age with hemophilia B for control and prevention of bleeding episodes, and for perioperative management.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

CONTRAINDICATIONS: IXINITY is contraindicated in patients who have known hypersensitivity to IXINITY or its excipients, including hamster protein.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions, including anaphylaxis, may occur following IXINITY administration. Discontinue use of IXINITY if hypersensitivity symptoms occur, and initiate appropriate treatment. Regularly evaluate patients for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected factor IX activity plasma levels are not attained, or, if bleeding is not controlled as expected with a certain dose, perform an assay that measures factor IX inhibitor concentration. An association between the occurrence of a factor IX inhibitor and allergic reactions has been reported. Individuals with factor IX inhibitors may be at increased risk of severe hypersensitivity reactions or anaphylaxis if re-challenged.

Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions.

Thromboembolism may occur when using IXINITY (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis).

Patients may develop hypersensitivity to hamster (CHO) protein as IXINITY contains trace amounts.

The most common adverse drug reaction observed in >2% of patients in clinical trials was headache.

Please see full Prescribing Information.

Medical Affairs e-mail: MedicalAffairs@apvo.com

To report an adverse event, please call 1-844-859-6675.

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Berwyn, PA; Aptevo BioTherapeutics LLC; August 2016.